Physician profile
Ruchi Agarwal
NPI 1720255813
$50,470.42
in general payments reported to CMS, 2019-2025
26 companies · $2,137 in 2025
The $2,137 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,931 · 2020: $7,363 · 2021: $3,738 · 2022: $9,986 · 2023: $15K · 2024: $5,886 · 2025: $2,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $22K · Food and Beverage: $1,143 · Travel and Lodging: $635 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $21,599.60 |
| Food and Beverage | $1,142.82 |
| Travel and Lodging | $635.24 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $31,884.00 | 2022-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $15,281.10 | 2019-2021 | |
| Abbvie INC. | $860.34 | 2019-2024 | Liletta |
| Avion Pharmaceuticals | $278.57 | 2020-2023 | Balcoltra |
| Exact Sciences Corporation | $254.05 | 2023-2025 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $228.84 | 2021-2025 | |
| Astellas Pharma US INC | $171.48 | 2025 | Veozah |
| Coopersurgical, INC. | $156.71 | 2019-2023 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $129.08 | 2019-2021 | |
| Myriad Women'S Health, INC. | $125.92 | 2023 | Myrisk |
| Therapeuticsmd, INC. | $124.85 | 2020-2022 | |
| Evofem Biosciences, INC. | $118.58 | 2020-2023 | Phexxi |
| Shield Therapeutics INC | $108.92 | 2024-2025 | |
| Agile Therapeutics, INC. | $107.76 | 2021-2023 | Twirla |
| Ironwood Pharmaceuticals, INC | $107.34 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $97.18 | 2025 | Slynd |
| Kci USA, INC. | $96.34 | 2019 | |
| Sumitomo Pharma America, INC. | $73.66 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $57.50 | 2021 | |
| Polarityte, INC. | $46.94 | 2019 | |
| Pfizer INC. | $42.03 | 2019 | |
| Allergan, INC. | $38.31 | 2019-2020 | |
| Scynexis, INC. | $23.85 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.74 | 2020 | |
| Amgen INC. | $19.44 | 2020 | |
| Lilly USA, LLC | $15.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchi Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.